<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               14 CLINICAL STUDIES<BR><BR>               <BR>                  Two randomized, double-blind, vehicle-controlled, clinical studies were conducted to evaluate ACZONE<BR>                     ® Gel, 5%, for the treatment of patients with acne vulgaris (N=1475 and 1525). The studies were designed to enroll patients 12 years of age and older with 20 to 50 inflammatory and 20 to 100 non-inflammatory lesions at baseline. In these studies patients applied either ACZONE<BR>                     ® Gel, 5%, or vehicle control twice daily for up to 12 weeks. Efficacy was evaluated in terms of success on the Global Acne Assessment Score (no or minimal acne) and in the percent reduction in inflammatory, non-inflammatory, and total lesions.<BR><BR>                  The Global Acne Assessment Score was a 5-point scale as follows:<BR><BR>                  0   None: no evidence of facial acne vulgaris<BR>1   Minimal: few non-inflammatory lesions (comedones) are present; a few inflammatory lesions (papules/pustules) may be present<BR>2   Mild: several to many non-inflammatory lesions (comedones) are present; a few inflammatory lesions (papules/pustules) are present<BR>3   Moderate: many non-inflammatory (comedones) and inflammatory lesions (papules/pustules) are present; no nodulo-cystic lesions are allowed<BR>4   Severe: significant degree of inflammatory disease; papules/pustules are a predominant feature; a few nodulo-cystic lesions may be present; comedones may be present.<BR><BR>                  The success rates on the Global Acne Assessment Score (no or minimal acne) at Week 12 are presented in Table 4.<BR><BR>                  <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:voc="urn:hl7-org:v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="t4" width="100%"><BR>                     <caption>Table 4 - Success (No or Minimal Acne) on the Global Acne Assessment Score at Week 12<BR></caption><BR>                     <col width="37.545%" align="left"/><BR>                     <col width="15.614%" align="left"/><BR>                     <col width="13.535%" align="left"/><BR>                     <col width="19.772%" align="left"/><BR>                     <col width="13.535%" align="left"/><BR>                     <tfoot><BR>                        <tr><BR>                           <td colspan="5" align="left" valign="top"><BR>                              <paragraph styleCode="footnote">*Analysis excludes subjects classified with minimal acne at baseline<BR></paragraph><BR>                           </td><BR>                        </tr><BR>                     </tfoot><BR>                     <tbody><BR>                        <tr><BR>                           <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/><BR>                           <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule">Study 1*<BR></td><BR>                           <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule">Study 2*<BR></td><BR>                        </tr><BR>                        <tr><BR>                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule"/><BR>                           <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                              <content styleCode="bold">ACZONE</content><BR>                              <sup>&#174;</sup><BR>                              <br/>N=699<BR></td><BR>                           <td align="left" valign="top" styleCode="Botrule Rrule">Vehicle<br/>N=687<BR></td><BR>                           <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                              <content styleCode="bold">ACZONE</content><BR>                              <sup>&#174;</sup><BR>                              <br/>N=729<BR></td><BR>                           <td align="left" valign="top" styleCode="Botrule Rrule">Vehicle<br/>N=738<BR></td><BR>                        </tr><BR>                        <tr><BR>                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Subjects with No or Minimal Acne<BR></td><BR>                           <td align="left" valign="top" styleCode="Botrule Rrule">291 (42%)<BR></td><BR>                           <td align="left" valign="top" styleCode="Botrule Rrule">223 (32%)<BR></td><BR>                           <td align="left" valign="top" styleCode="Botrule Rrule">253 (35%)<BR></td><BR>                           <td align="left" valign="top" styleCode="Botrule Rrule">206 (28%)<BR></td><BR>                        </tr><BR>                     </tbody><BR>                  </table><BR>                  <BR><BR><BR><BR>                     Table 5 presents the mean percent reduction in inflammatory, non-inflammatory, and total lesions from baseline to Week 12.<BR><BR>                  <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:voc="urn:hl7-org:v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="t5" width="100%"><BR>                     <caption>Table 5 - Percent Reduction in Lesions from Baseline to Week 12<BR></caption><BR>                     <col width="37.545%" align="left"/><BR>                     <col width="15.614%" align="left"/><BR>                     <col width="13.535%" align="left"/><BR>                     <col width="19.772%" align="left"/><BR>                     <col width="13.535%" align="left"/><BR>                     <tbody><BR>                        <tr><BR>                           <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/><BR>                           <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule">Study 1<BR></td><BR>                           <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule">Study 2<BR></td><BR>                        </tr><BR>                        <tr><BR>                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule"/><BR>                           <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                              <content styleCode="bold">ACZONE</content><BR>                              <sup>&#174;</sup><BR>                              <br/>N=745<BR></td><BR>                           <td align="left" valign="top" styleCode="Botrule Rrule">Vehicle<br/>N=740<BR></td><BR>                           <td align="left" valign="top" styleCode="Botrule Rrule"><BR>                              <content styleCode="bold">ACZONE</content><BR>                              <sup>&#174;</sup><BR>                              <br/>N=761<BR></td><BR>                           <td align="left" valign="top" styleCode="Botrule Rrule">Vehicle<br/>N=764<BR></td><BR>                        </tr><BR>                        <tr><BR>                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Inflammatory<BR></td><BR>                           <td align="left" valign="top" styleCode="Botrule Rrule">46%<BR></td><BR>                           <td align="left" valign="top" styleCode="Botrule Rrule">42%<BR></td><BR>                           <td align="left" valign="top" styleCode="Botrule Rrule">48%<BR></td><BR>                           <td align="left" valign="top" styleCode="Botrule Rrule">40%<BR></td><BR>                        </tr><BR>                        <tr><BR>                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Non-Inflammatory<BR></td><BR>                           <td align="left" valign="top" styleCode="Botrule Rrule">31%<BR></td><BR>                           <td align="left" valign="top" styleCode="Botrule Rrule">24%<BR></td><BR>                           <td align="left" valign="top" styleCode="Botrule Rrule">30%<BR></td><BR>                           <td align="left" valign="top" styleCode="Botrule Rrule">21%<BR></td><BR>                        </tr><BR>                        <tr><BR>                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Total<BR></td><BR>                           <td align="left" valign="top" styleCode="Botrule Rrule">38%<BR></td><BR>                           <td align="left" valign="top" styleCode="Botrule Rrule">32%<BR></td><BR>                           <td align="left" valign="top" styleCode="Botrule Rrule">37%<BR></td><BR>                           <td align="left" valign="top" styleCode="Botrule Rrule">29%<BR></td><BR>                        </tr><BR>                     </tbody><BR>                  </table><BR>                  <BR><BR><BR>The clinical studies enrolled about equal proportions of male and female subjects. Female patients tended to have greater percent reductions in lesions and greater success on the Global Acne Assessment Score than males. The breakdown by race in the clinical studies was about 73% Caucasian, 14% Black, 9% Hispanic, and 2% Asian. Efficacy results were similar across the racial subgroups.<BR><BR>               <BR>               <BR>            <BR>         </P></DIV></HTML>